US Ambassador visit signals closer American links for Cerbios-Pharma
Press Release | Cerbios-Pharma SA
DECEMBER 06, 2018
Lugano, Switzerland: – Pharmaceutical ingredient specialist Cerbios-Pharma SA (Cerbios) recently played host to the US Ambassador to Switzerland, as an important signal of its increasing links with the USA.
Edward McMullen Jr., US Ambassador to Switzerland and Liechtenstein, spent a day in September visiting the Cerbios headquarters in Lugano in Ticino, meeting top management and shareholders, as well as viewing the advanced research and manufacturing facilities.
The aim of the visit was to give the Ambassador a better view and understanding of Cerbios’ ongoing and future activities in the USA.
Cerbios has been active in North America since 1982, establishing leadership with its reduced folates products used in oncology. In the past years, activities have strongly increased as service provider and CDMO (Contract Development and Manufacturing Operation) for originators needing Cerbios’ expertise and know-how in handling and producing new generation High Potency Active Ingredients (HPAIs) and Antibody Drug Conjugates (ADCs).
Closer links with USA
“It is our goal to support Cerbios and other Swiss companies in strengthening their activities in the United States,” said Ambassador McMullen.
“I was really positively surprised to discover not only Cerbios’ unique and innovative activities but also that a small canton like Ticino has an important Pharmaceutical Cluster heavily contributing to the canton’s GDP,” he added.
Cerbios CEO. Dr. Gabriel Haering, commented: “Cerbios’ forecasted growth in the coming years means an increased presence in the USA.”
“Establishing an affiliate company through acquisition or a joint venture is an option we are considering in order to better serve our partners locally. The support of the US Embassy in Bern has really been remarkable till now,” said Dr. Haering.
Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacturing of both chemical and biological APIs for its partners world-wide.
Cerbios’ is a global leading supplier of a portfolio of Generic APIs primarily used in Oncology as well as in the treatment of Respiratory and Dermatological disorders.
Exclusive CDMO services are offered for the development and manufacturing of high potency active ingredients (HPAIs) as well as for biological products including monoclonal antibodies, recombinant proteins, antibody drug conjugates (ADCs) and pharma probiotics.
Cerbios provides full CMC support, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs, with paramount ability to supply all technical documentation and support necessary for successful registration. Cerbios’ commercial products are marketed worldwide, primarily in Europe, USA, Japan and India.
Since 2015, Cerbios has been a member of the ADC manufacture PROVEO™ consortium, forged with AGC Biologics of Denmark and with Germany’s Oncotec.
PROVEO can offer an ADCs end-to-end service from substance development through manufacturing to fill & finish.
Chiara Brusadelli, Commercial Operations Specialist, Cerbios-Pharma SA
Tel: +41 91 9856311